Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2025)

Xeris Biopharma Holdings' EBT Margin history spans 6 years, with the latest figure at 12.91% for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 2142.0% year-over-year to 12.91%, compared with a TTM value of 0.19% through Dec 2025, up 2831.0%, and an annual FY2025 reading of 0.19%, up 2831.0% over the prior year.
  • EBT Margin for Q4 2025 was 12.91% at Xeris Biopharma Holdings, up from 0.83% in the prior quarter.
  • The five-year high for EBT Margin was 12.91% in Q4 2025, with the low at 308.95% in Q2 2021.
  • Average EBT Margin over 5 years is 83.23%, with a median of 42.99% recorded in 2022.
  • Year-over-year, EBT Margin crashed -6495bps in 2021 and then skyrocketed 20414bps in 2022.
  • Tracing XERS's EBT Margin over 5 years: stood at 237.02% in 2021, then skyrocketed by 83bps to 40.03% in 2022, then rose by 23bps to 30.7% in 2023, then skyrocketed by 72bps to 8.51% in 2024, then soared by 252bps to 12.91% in 2025.
  • Per Business Quant, the three most recent readings for XERS's EBT Margin are 12.91% (Q4 2025), 0.83% (Q3 2025), and 2.7% (Q2 2025).